Indy Sandaradura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6920929/publications.pdf Version: 2024-02-01



#	ARTICLE	IF	CITATIONS
1	Emerging therapeutic drug monitoring of antiâ€infective agents in Australian hospitals: Availability, performance and barriers to implementation. British Journal of Clinical Pharmacology, 2022, 88, 669-679.	2.4	23
2	Does Prolonged Infusion Time Really Improve the Efficacy of Meropenem Therapy? A Prospective Study in Critically III Patients. Infectious Diseases and Therapy, 2022, 11, 201-216.	4.0	6
3	Optimal Practice for Vancomycin Therapeutic Drug Monitoring: Position Statement From the Anti-infectives Committee of the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2022, 44, 121-132.	2.0	18
4	Multidrug-resistant OXA-48/CTX-M-15 Klebsiella pneumoniae cluster in a COVID-19 intensive care unit: salient lessons for infection prevention and control during the COVID-19 pandemic. Journal of Hospital Infection, 2022, 126, 64-69.	2.9	3
5	C/MIC > 4: A Potential Instrument to Predict the Efficacy of Meropenem. Antibiotics, 2022, 11, 670.	3.7	1
6	Current fluconazole treatment regimens result in under-dosing of critically ill adults during early therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2021, 40, 1521-1528.	2.9	5
7	Model-Optimized Fluconazole Dose Selection for Critically III Patients Improves Early Pharmacodynamic Target Attainment without the Need for Therapeutic Drug Monitoring. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	6
8	Optimization of Fluconazole Dosing for the Prevention and Treatment of Invasive Candidiasis Based on the Pharmacokinetics of Fluconazole in Critically III Patients. Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	15
9	Therapeutic Drug Monitoring in Non-Tuberculosis Mycobacteria Infections. Clinical Pharmacokinetics, 2021, 60, 711-725.	3.5	23
10	Are vancomycin dosing guidelines followed? A mixed methods study of vancomycin prescribing practices. British Journal of Clinical Pharmacology, 2021, 87, 4221-4229.	2.4	16
11	Reply to Van Daele et al., "Fluconazole Underexposure in Critically Ill Patients: a Matter of Using the Right Targets?― Antimicrobial Agents and Chemotherapy, 2021, 65, .	3.2	1
12	A Large Sample Retrospective Study on the Distinction of Voriconazole Concentration in Asian Patients from Different Clinical Departments. Pharmaceuticals, 2021, 14, 1239.	3.8	5
13	Factors Affecting Voriconazole Trough Concentration and Optimal Maintenance Voriconazole Dose in Chinese Children. Antibiotics, 2021, 10, 1542.	3.7	8
14	Phage therapy for severe bacterial infections: a narrative review. Medical Journal of Australia, 2020, 212, 279-285.	1.7	37
15	The Antibody Response to SARS-CoV-2 Infection. Open Forum Infectious Diseases, 2020, 7, ofaa387.	0.9	45
16	Therapeutic drug monitoring of commonly used anti-infective agents: A nationwide cross-sectional survey of Australian hospital practices. International Journal of Antimicrobial Agents, 2020, 56, 106180.	2.5	17
17	Clinical evaluation of SARS-CoV-2 point-of-care antibody tests. Pathology, 2020, 52, 783-789.	0.6	9
18	Safety of bacteriophage therapy in severe Staphylococcus aureus infection. Nature Microbiology, 2020, 5, 465-472.	13.3	258

2

#	Article	IF	CITATIONS
19	A close shave? Performance of P2/N95 respirators in healthcare workers with facial hair: results of the BEARDS (BEnchmarking Adequate Respiratory DefenceS) study. Journal of Hospital Infection, 2020, 104, 529-533.	2.9	47
20	An evaluation of the userâ€friendliness of Bayesian forecasting programs in a clinical setting. British Journal of Clinical Pharmacology, 2019, 85, 2436-2441.	2.4	27
21	Influenza: overview on prevention and therapy. Australian Prescriber, 2019, 42, 51.	1.0	9
22	Pathology at the clinical bedside: Bringing digital microbiology to the intensive care unit. Pathology, 2019, 51, S70.	0.6	0
23	Urinary piperacillin/tazobactam pharmacokinetics in vitro to determine the pharmacodynamic breakpoint for resistant Enterobacteriaceae. International Journal of Antimicrobial Agents, 2019, 54, 240-244.	2.5	10
24	Flucloxacillin therapeutic drug monitoring in a neonate on extracorporeal membrane oxygenation. Journal of Paediatrics and Child Health, 2019, 55, 246-247.	0.8	1
25	New Formulation Suba-Itraconazole Prophylaxis in Patients with Haematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, S335-S336.	2.0	1
26	Evaluation of Tobramycin Exposure Predictions in Three Bayesian Forecasting Programmes Compared with Current Clinical Practice in Children and Adults with Cystic Fibrosis. Clinical Pharmacokinetics, 2018, 57, 1017-1027.	3.5	17
27	1139. Novel Formulation SUBA-Itraconazole Prophylaxis in Patients With Hematological Malignancy or Undergoing Allogeneic Stem Cell Transplantation: Follow-up Survival Data. Open Forum Infectious Diseases, 2018, 5, S342-S342.	0.9	1
28	Barriers and facilitators of appropriate vancomycin use: prescribing context is key. European Journal of Clinical Pharmacology, 2018, 74, 1523-1529.	1.9	15
29	An evaluation of risk factors to predict target concentration non-attainment in critically ill patients prior to empiric β-lactam therapy. European Journal of Clinical Microbiology and Infectious Diseases, 2018, 37, 2171-2175.	2.9	22
30	Establishment of an AUC _{0–24} Threshold for Nephrotoxicity Is a Step towards Individualized Vancomycin Dosing for Methicillin-Resistant Staphylococcus aureus Bacteremia. Antimicrobial Agents and Chemotherapy, 2017, 61, .	3.2	75
31	Serum levels, safety and tolerability of new formulation SUBA-itraconazole prophylaxis in patients with haematological malignancy or undergoing allogeneic stem cell transplantation. Journal of Antimicrobial Chemotherapy, 2017, 72, 3414-3419.	3.0	43
32	Too much of a good thing: a retrospective study of β-lactam concentration–toxicity relationships. Journal of Antimicrobial Chemotherapy, 2017, 72, 2891-2897.	3.0	188
33	Redesign of computerized decision support to improve antimicrobial prescribing. Applied Clinical Informatics, 2017, 08, 949-963.	1.7	24
34	<i>Angiostrongylus cantonensis</i> : a review of its distribution, molecular biology and clinical significance as a human pathogen. Parasitology, 2016, 143, 1087-1118.	1.5	162
35	Documenting antibiotic use in transition from intensive care unit to wards. Journal of Pharmacy Practice and Research, 2016, 46, 91-92.	0.8	1
36	Posaconazole Plasma Concentrations during Intravenous to Oral Tablet Crossover: Are Variations Due to Distribution and Metabolism Rather Than Absorption?. Biology of Blood and Marrow Transplantation, 2016, 22, S475-S476.	2.0	1

#	Article	IF	CITATIONS
37	Non-susceptibility to ceftaroline in healthcare-associated multiresistant MRSA in Eastern Australia. Journal of Antimicrobial Chemotherapy, 2015, 70, 2413-2414.	3.0	8
38	Molecular Epidemiology of Imported Cases of Leishmaniasis in Australia from 2008 to 2014. PLoS ONE, 2015, 10, e0119212.	2.5	17
39	Cardiac cysticercosis. International Journal of Cardiology, 2013, 168, 557-559.	1.7	11
40	Update on antimicrobial resistance: mechanisms, methods and practice. Pathology, 2012, 44, S48.	0.6	0
41	Disability after encephalitis: development and validation of a new outcome score. Bulletin of the World Health Organization, 2010, 88, 584-592.	3.3	50